Skindex-29

1. Abstract

The Skindex-29 is an internationally recognized, dermatology-specific patient-reported outcome measure (PROM) developed by Dr. Mary-Margaret Chren and colleagues to evaluate the multi-dimensional impact of dermatological conditions on health-related quality of life (HRQoL). Arising from iterative refinements of the original 61-item Skindex instrument, the Skindex-29 comprises 29 self-report items grouped into three rigorously validated clinical domains: Symptoms (7 items), Emotions (10 items), and Functioning (12 items). Each item gauges how frequently skin conditions have affected the respondent over a seven-day recall window using a 5-point Likert scale ranging from Never to All the time. Item responses are linearly transformed into a normalized 0 to 100 metric, where higher composite and domain scores reflect greater degrees of impairment and diminished well-being.

Extensive psychometric investigations across diverse international cohorts—including inflammatory diseases such as psoriasis and atopic dermatitis, autoimmune conditions, and cutaneous malignancies—demonstrate exemplary psychometric robustness. The instrument exhibits internal consistency reliability coefficients routinely exceeding 0.85 to 0.95 across all domains, test-retest intraclass correlation coefficients (ICC) ranging between 0.86 and 0.92, and robust construct, convergent, and discriminant validity against generic health surveys such as the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and dermatology-specific instruments like the Dermatology Life Quality Index (DLQI). Confirmatory factor analyses consistently substantiate the hypothesized three-factor latent structure. Widely adapted into over 30 languages, the Skindex-29 serves as a gold-standard assessment tool in both clinical dermatology trials and epidemiological psychodermatology investigations.

2. Keywords

Skindex-29, Health-Related Quality of Life, Dermatology, Psychodermatology, Psychometrics, Patient-Reported Outcome Measure, Cutaneous Disease, Validation, Reliability, Factor Analysis

3. Authors

The primary architect of the Skindex measurement system is Mary-Margaret Chren, MD, Professor Emerita of Dermatology at the University of California, San Francisco (UCSF) and previously affiliated with Case Western Reserve University and the Cleveland Veterans Affairs Medical Center. Dr. Chren developed the original conceptual models and empirical item reduction strategies alongside a multidisciplinary team of dermatologists, psychometricians, and health services researchers, including Richard J. Lasek, MD, MA, and David N. Quinn, MD.

International cross-cultural adaptations and structural validations have been spearheaded by prominent dermatological methodologists, notably Jan de Korte, PhD, and colleagues at the Academic Medical Center, University of Amsterdam (Netherlands), who validated the Dutch translation and contributed foundational work on category cut-off scores, and Luigi Naldi, MD, along with the Italian Study Group on Quality of Life in Dermatology.

4. Purpose

Cutaneous pathology presents unique clinical challenges: skin diseases are rarely immediately fatal, yet their visibility, physical discomfort, and chronicity exert a profound psychological and psychosocial toll. Traditional objective clinical scoring instruments—such as the Psoriasis Area and Severity Index (PASI) or the Scoring Atopic Dermatitis (SCORAD)—correlate only moderately with the patient’s lived subjective experience. The primary purpose of the Skindex-29 is to bridge this critical evaluative gap by providing an empirically grounded, patient-centered index measuring the precise degree to which skin disorders impair daily functioning, emotional equilibrium, and somatic comfort.

In clinical practice, the Skindex-29 aids clinicians in identifying hidden psychosocial morbidity, facilitating structured dialogues regarding the non-visible burdens of dermatological conditions (e.g., stigmatization, sexual dysfunction, sleep architecture disruption). In clinical trial environments, the scale operates as a sensitive primary or secondary endpoint to gauge therapeutic efficacy, drug responsiveness, and comparative effectiveness of systemic biologics, targeted small molecules, or phototherapy regimens. Furthermore, the instrument facilitates health economic evaluations, enabling quality-adjusted life year (QALY) estimations and supporting policy decisions regarding the reimbursement of advanced dermatological therapeutics.

5. Psychological Construct

The Skindex-29 measures the overarching construct of Dermatology-Specific Health-Related Quality of Life (HRQoL), structured across three interdependent yet distinct latent dimensions:

5.1. Symptoms Domain

The Symptoms subscale encapsulates the physical and somatic sensations inherently tied to cutaneous pathophysiology. Comprising 7 items, this domain targets sensations that are directly registered by nociceptors and pruriceptors within the epidermal and dermal layers. Measured experiences include cutaneous pain (“My skin hurts”), pruritus (“My skin itches”), burning or stinging (“My skin condition burns or stings”), localized bleeding (“My skin bleeds”), persistent irritation, cutaneous sensitivity, and weeping/exudation (“My skin condition drains or weeps”). This subscale is uniquely responsive to acute inflammatory exacerbations and somatic symptom attenuation following pharmacological intervention.

5.2. Emotions Domain

The Emotions subscale quantifies the psychological distress, affective disturbances, and cognitive appraisals triggered by skin disease. Composed of 10 items, this dimension addresses internalized stigma, anticipatory anxiety, and mood dysregulation. Specific items evaluate feelings of embarrassment (“My skin condition makes me feel embarrassed”), shame (“I feel ashamed of my skin condition”), depression (“My skin condition makes me feel depressed”), anger, humiliation, and frustration. In addition, it measures illness anxiety, specifically health-related worry regarding disease progression (“I worry that my skin condition will get worse”) and secondary physical complications such as permanent scarring (“I worry about getting scars from my skin condition”). This domain systematically captures the pervasive psychological burden characteristic of psychodermatological pathology.

5.3. Functioning Domain

The Functioning subscale measures the behavioral, interpersonal, and functional consequences of dermatological conditions across domestic, social, and vocational contexts. Spanning 12 items, it examines functional role impairments including sleep disruption (“My skin condition affects how well I sleep”), restrictions on occupational tasks and hobbies (“My skin condition makes it hard to work or do hobbies”), social avoidance or home confinement (“I tend to stay at home because of my skin condition”), and the loss of behavioral spontaneity (“My skin condition makes it hard to be spontaneous”). Furthermore, it examines interpersonal intimacy, affection, and sexual functioning (“My skin condition interferes with my sex life”), as well as secondary family distress (“My skin condition makes it difficult to do things with my family” and “My skin condition is a problem for the people I love”).

6. Theoretical Framework

The structural design of the Skindex-29 is deeply anchored in the Biopsychosocial Model proposed by George Engel (1977), which conceptualizes health and disease as the dynamic interplay between biological, psychological, and socio-environmental factors. In dermatology, the skin functions not merely as an anatomical barrier, but as a vital neuro-immuno-cutaneous organ and an essential medium for social communication, tactile intimacy, and self-identity.

The scale also operationalizes the classic Wilson and Cleary Model of Patient Outcomes (1995), which links biological and physiological variables directly to symptom status, general health perceptions, functional status, and overall quality of life:

• Biological/Physiological Layer: Epidermal barrier disruption, immune cell infiltration, cytokine release.
• Symptom Status: Sensory registration of itching, burning, soreness (captured by the Symptoms subscale).
• Functional Status: Behavioral changes in sleep, work, recreation, and sexual intimacy (captured by the Functioning subscale).
• Health Perceptions & Affect: Cognitive appraisal of disease severity, self-blame, stigmatization, and chronic demoralization (captured by the Emotions subscale).

Additionally, the instrument draws on Erving Goffman’s sociological treatise on Stigma (1963). Dermatological lesions are frequently visible to others, violating societal conventions of physical appearance. Goffman described “spoiled identity,” wherein individuals possess an attribute that marks them as culturally devalued. The Skindex-29 systematically operationalizes this through items assessing shame, humiliation, perceived social rejection, and avoidance behaviors, capturing the profound interaction between outward physical appearance and inward subjective distress.

7. Validity

The psychometric validity of the Skindex-29 has been extensively verified across multiple international cohorts and clinical settings:

7.1. Content and Face Validity

Content validity was established through rigorous qualitative methodologies during the initial construction of the Skindex item pool. Chren et al. extracted items directly from qualitative focus groups, open-ended clinical interviews with dermatology patients, and expert reviews by clinical dermatologists. Cognitive debriefing sessions confirmed that the 29 items thoroughly cover the spectrum of physical, emotional, and social concerns without redundant burden.

7.2. Construct and Convergent Validity

Construct validity has been demonstrated via convergent correlations with established generic and disease-specific health instruments. In convergent validity analyses, the Skindex-29 Emotions domain exhibits strong negative correlations with the Mental Health and Vitality subscales of the SF-36 ($r = -0.65$ to $-0.78$), whereas the Symptoms domain correlates strongly with the SF-36 Bodily Pain subscale ($r = -0.58$ to $-0.72$). When compared against the Dermatology Life Quality Index (DLQI), aggregate and domain-level Skindex-29 scores show high convergent correlations ($r = 0.70$ to $0.85$), confirming that both instruments capture shared aspects of cutaneous morbidity while Skindex-29 offers greater emotional granularity.

7.3. Discriminant and Known-Groups Validity

The instrument reliably discriminates between clinical cohorts with varying objective disease severity. Patients categorized by clinicians as having severe manifestations of psoriasis, atopic eczema, or cutaneous lupus erythematosus consistently score significantly higher across all domains ($p < 0.001$) compared to patients with mild or localized presentations. Furthermore, the Skindex-29 demonstrates distinct domain divergence: inflammatory conditions (e.g., eczema, hidradenitis suppurativa) yield disproportionately elevated Symptoms scores, whereas disfiguring but asymptomatic lesions (e.g., facial vitiligo, alopecia areata) exhibit high Emotions scores paired with low Symptoms scores.

7.4. Responsiveness to Change

Longitudinal clinical trials demonstrate high sensitivity to clinical improvement (responsiveness). Following successful dermatological interventions (e.g., targeted biologics, phototherapy, or topical corticosteroids), Skindex-29 scores decrease significantly, with standardized effect sizes (Cohen’s $d$) frequently exceeding $0.80$ for the Symptoms and Emotions subscales among clinical responders.

8. Reliability

The Skindex-29 consistently exhibits high internal consistency and temporal stability:

8.1. Internal Consistency

Across validation studies conducted in the United States, Netherlands, Italy, Germany, France, Spain, and East Asia, Cronbach’s alpha coefficients exceed standard psychometric thresholds across all three subscales:

• Symptoms Subscale: $\alpha = 0.86 – 0.91$
• Emotions Subscale: $\alpha = 0.93 – 0.96$
• Functioning Subscale: $\alpha = 0.89 – 0.94$

Item-total correlation coefficients consistently fall between $0.50$ and $0.82$, confirming strong internal coherence without item redundancy.

8.2. Test-Retest Reliability

Test-retest stability has been evaluated over intervals ranging from 72 hours to two weeks among clinically stable patients. Intraclass correlation coefficients (ICC) confirm robust temporal reproducibility:

• Symptoms: $\text{ICC} = 0.86 – 0.91$
• Emotions: $\text{ICC} = 0.88 – 0.92$
• Functioning: $\text{ICC} = 0.87 – 0.93$

Bland-Altman limits of agreement demonstrate negligible systematic bias between test administrations, confirming the instrument’s stability for repeated measurements.

9. Factor Analysis

The structural dimensionality of the Skindex-29 was initially determined using Exploratory Factor Analysis (EFA) with principal component extraction and oblique rotation (Promax/Oblimin), reflecting the expected biological and psychological intercorrelations between health domains.

9.1. Factor Loadings

EFA consistently extracts three primary factors accounting for over $60%$ to $68%$ of the total variance across clinical samples:

• Factor 1 (Emotions): Items 3, 6, 9, 12, 15, 18, 21, 23, 26, and 28 load strongly on this factor (salient loadings: $lambda = 0.62 – 0.88$), reflecting affective burden and anxiety.
• Factor 2 (Functioning): Items 2, 4, 8, 11, 13, 14, 17, 20, 22, 25, and 29 display primary loadings between $lambda = 0.58$ and $0.84$, capturing social, occupational, and interpersonal interference.
• Factor 3 (Symptoms): Items 1, 7, 10, 16, 19, 24, and 27 demonstrate distinctive physical symptom loadings ranging from $lambda = 0.55$ to $0.86$.

Cross-loadings are generally minimal, with the occasional exception of Item 18 (“My skin condition is a problem for the people I love”), which shows moderate secondary loadings across both Emotions and Functioning, reflecting its dual psychosocial nature.

9.2. Confirmatory Factor Analysis (CFA) & Model Fit

Subsequent Confirmatory Factor Analyses (CFA) across diverse linguistic and cultural populations have verified the fit of the hypothesized three-factor oblique model. Standard goodness-of-fit indices confirm solid psychometric alignment:

• Root Mean Square Error of Approximation (RMSEA): $0.048 – 0.065$ (indicating good model fit)
• Comparative Fit Index (CFI): $0.94 – 0.98$
• Tucker-Lewis Index (TLI): $0.93 – 0.97$
• Standardized Root Mean Square Residual (SRMR): $0.041 – 0.055$

Multigroup invariance testing (configural, metric, and scalar invariance) supports cross-cultural equivalence across European, North American, and Asian translations.

10. Instrument / Measurement Tool

• Tool Name: Skindex-29
• Instrument Type: Dermatology-specific health-related quality of life patient-reported outcome measure (PROM)
• Administration Format: Self-administered paper-and-pencil or validated electronic questionnaire (ePRO)
• Target Population: Adult and elderly patients presenting with any dermatological pathology
• Number of Items: 29 items
• Recall Period: Past 7 days (the previous week)
• Response Scale: 5-point Likert scale: 1 = Never, 2 = Rarely, 3 = Sometimes, 4 = Often, 5 = All the time (scored 0, 25, 50, 75, 100)
• Domain Breakdown:
  • Symptoms Subscale (7 items): Items 1, 7, 10, 16, 19, 24, 27
  • Emotions Subscale (10 items): Items 3, 6, 9, 12, 15, 18, 21, 23, 26, 28
  • Functioning Subscale (12 items): Items 2, 4, 8, 11, 13, 14, 17, 20, 22, 25, 29
  • Note: Item 18 is analyzed within the Emotions domain, but may also be examined independently as a marker of interpersonal family burden.
• Scoring and Transformation Rules:
  • Item responses are converted to a 100-point metric: Never = 0, Rarely = 25, Sometimes = 50, Often = 75, All the time = 100.
  • Domain scores are calculated as the mean score of the completed items within each subscale. Scores range from 0 (no effect on HRQoL) to 100 (maximum negative impact on HRQoL).
  • Missing data rule: If a respondent answers fewer than $75%$ of the items within a given subscale, that subscale score cannot be reliably computed.
• Interpretive Cut-Off Bands (Prinsen et al., 2011):
  • Symptoms: Mild ($le 27$), Moderate ($28 – 43$), Severe ($ge 44$)
  • Emotions: Mild ($le 24$), Moderate ($25 – 49$), Severe ($ge 50$)
  • Functioning: Mild ($le 18$), Moderate ($19 – 36$), Severe ($ge 37$)

11. Permissions & Fee and Test Year

The original Skindex measurement framework was introduced by Dr. Mary-Margaret Chren in 1996, with the revised 29-item version (Skindex-29) published in 1997. The instrument is copyrighted by Dr. Mary-Margaret Chren.

Licensing and Distribution: The Skindex-29, its validated linguistic translations, and electronic implementations are managed and distributed through Mapi Research Trust via the ePROVIDE platform.

• Academic and Non-Commercial Research: Generally granted royalty-free or at low administrative processing costs for academic researchers, individual clinicians, and non-funded clinical investigations upon completion of a formal User Agreement.
• Commercial and Funded Clinical Trials: Pharmaceutical companies, contract research organizations (CROs), and commercial entities must obtain a paid license covering user fees, linguistic certification, and digital migration rights.

For licensing inquiries, translation permissions, or scoring manuals, researchers should contact the Mapi Research Trust PROVIDE service in Lyon, France.

12. References

Chren, M. M., Lasek, R. J., Quinn, L. M., Mostow, E. N., & Zyzanski, S. J. (1996). Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. Journal of Investigative Dermatology, 107(5), 707–713. https://doi.org/10.1111/1523-1747.ep12365600

Chren, M. M., Lasek, R. J., Flocke, S. A., & Zyzanski, S. J. (1997). Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Archives of Dermatology, 133(11), 1433–1440. https://doi.org/10.1001/archderm.1997.03890470111018

de Korte, J., Mombers, F. M., Sprangers, M. A., & Bos, J. D. (2003). The Dutch version of the Skindex-29: psychometric properties and responsiveness in patients with skin diseases. Quality of Life Research, 12(6), 713–722. https://doi.org/10.1023/A:1025178619379

Naldi, L., Gallus, S., & Imberti, G. L. (2004). The impact of skin disease on quality of life: psychometric properties of the Italian version of Skindex-29. Health and Quality of Life Outcomes, 2, Article 53. https://doi.org/10.1186/1477-7525-2-53

Prinsen, C. A., Lindeboom, R., & de Korte, J. (2011). Interpretation of Skindex-29 scores: cut-off scores for assessing the effects of skin diseases on quality of life. British Journal of Dermatology, 165(6), 1245–1251. https://doi.org/10.1111/j.1365-2133.2011.10543.x

Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life: A conceptual model of patient outcomes. JAMA, 273(1), 59–65. https://doi.org/10.1001/jama.1995.03520250075037

13. Items of the Scale